Godavari Biorefineries Secures Chinese Patent for Antiviral Compounds Targeting V-ATPase

Godavari Biorefineries Limited (GBL) announced that the China National Intellectual Property Administration (CNIPA) officially granted patent number ZL 2021 8 0048053.9 on September 15, 2026. The patent covers the use of specific chemical compounds for treating viral infections by targeting the inhibition of V-ATPase activity within cells.

This milestone adds to GBL’s expanding global intellectual property portfolio in the biopharmaceutical space, which already includes a Japanese patent for viral infection treatments and European patents related to biodegradable biofillers and anticancer molecules. The Chinese patent application was originally filed on May 10, 2021, reflecting a development timeline of over five years.

The patented technology is being developed under GBL’s biopharmaceutical R&D division, Sathgen Therapeutics, underscoring the company’s capability to generate innovative global IP assets. However, the company cautions that drug discovery and development involve prolonged clinical trial and regulatory pathways, meaning commercial returns from this patent are expected only in the long term.

In the near term, GBL’s financial performance continues to be influenced primarily by its core biochemical and ethanol processing operations. For the first quarter of fiscal year 2027 (Q1 FY27), the company reported revenue from operations of ₹557.9 crore, a 4.6% increase year-on-year from ₹533.2 crore. Despite this revenue growth, EBITDA contracted sharply by 60.5% to ₹2.6 crore from ₹6.5 crore in the same quarter last year.

This decline in profitability contributed to a widened net loss of ₹19.3 crore in Q1 FY27, compared to a net loss of ₹16.0 crore in Q1 FY26. Consolidated EBITDA margins fell from 1.2% to 0.5%, reflecting margin pressures and increased costs in the integrated sugar and co-generation segments.

GBL’s near-term stock performance and valuation remain closely tied to commodity sugar and ethanol market cycles, sugarcane crop yields, and government policies on ethanol blending. The company recently commissioned a 200 KLPD grain-based distillery at Sameerwadi, raising its total ethanol production capacity to 800 KLPD and enhancing feedstock flexibility.

Alongside the Chinese patent, GBL also secured a European patent (EP3313916) on September 5, 2026, for a biodegradable biofiller designed to replace carbon black in rubber reinforcement. However, the company faces regulatory challenges, including a ₹17.02 crore show cause notice issued by the Central GST Audit in Belagavi concerning non-payment of GST on the supply of Extra Neutral Alcohol (ENA) fit for human consumption in Karnataka.

While the expansion of GBL’s high-tech and biopharmaceutical patent portfolio strengthens its long-term strategic positioning, the company remains fundamentally anchored in bio-based chemicals and ethanol blending. Operational efficiency improvements and stabilization of crop cycles are critical to supporting its valuation and enabling future growth.

In summary, the Chinese patent grant represents a significant R&D achievement for Godavari Biorefineries, reinforcing its global IP footprint in antiviral therapeutics. Nonetheless, immediate commercial impact is limited, and near-term financial results continue to be shaped by traditional commodity business dynamics and regulatory factors.